Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Northwest Biotherapeutics: (NWBO, Buy, $0.35) Management Issues Guidance That DCVax-L Phase 3 Trial Results Will Be Released Sometime After Labor Day

Investment Overview: Highly Asymmetric Outlook

Northwest Biotherapeutics has guided that it will report results of the phase 3 trial of DCVax-L…
Read more…